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Abstract
Background: Impaired insulin signalling is increasingly thought to contribute to Alzheimer’s disease (AD). The e4 isoform of
the APOE gene is the greatest genetic risk factor for sporadic, late onset AD, and is also associated with risk for type 2
diabetes mellitus (T2DM). Neuropathological studies reported the highest number of AD lesions in brain tissue of e4
diabetic patients. However other studies assessing AD pathology amongst the diabetic population have produced
conflicting reports and have failed to show an increase in AD-related pathology in diabetic brain. The thiazolidinediones
(TZDs), peroxisome proliferator-activated receptor gamma agonists, are peripheral insulin sensitisers used to treat T2DM.
The TZD, pioglitazone, improved memory and cognitive functions in mild to moderate AD patients. Since it is not yet clear
how apoE isoforms influence the development of T2DM and its progression to AD, we investigated amyloid beta and tau
pathology in APOE knockout mice, carrying human APOEe3o re4 transgenes after diet-induced insulin resistance with and
without pioglitazone treatment.
Methods: Male APOE knockout, APOEe3-transgenic and APOEe4-transgenic mice, together with background strain C57BL6
mice were kept on a high fat diet (HFD) or low fat diet (LFD) for 32 weeks, or were all fed HFD for 32 weeks and during the
final 3 weeks animals were treated with pioglitazone or vehicle.
Results: All HFD animals developed hyperglycaemia with elevated plasma insulin. Tau phosphorylation was reduced at 3
epitopes (Ser396, Ser202/Thr205 and Thr231) in all HFD, compared to LFD, animals independent of APOE genotype. The
introduction of pioglitazone to HFD animals led to a significant reduction in tau phosphorylation at the Ser202/Thr205
epitope in APOEe3 animals only. We found no changes in APP processing however the levels of soluble amyloid beta 40 was
reduced in APOE knockout animals treated with pioglitazone.
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Introduction
The concept that impaired insulin signalling influences neurode-
generative mechanisms in Alzheimer’s disease (AD) and leads to
impairment in cognitive processes is attracting increasing attention.
This hypothesis was prompted by the clinical investigations
showing the reduction of glucose utilisation in the AD brain [1].
Subsequently, experimentally induced brain insulin resistance
models have shown that altered insulin signalling causes cognitive
deficits and, at least in some instances influences aspects of AD
pathology [2,3]. Interestingly, reduced levels of insulin, insulin-like
growth factor receptors and insulin degrading enzyme have been
reported in brain tissue from AD patients [4,5]. In addition there
have been reports of low cerebrospinal fluid (CSF) to plasma insulin
ratio in AD patients, which is influenced by APOE genotype [6].
The e4 isoform of the APOE gene is the most significant genetic
risk factor for AD [7]. Type 2 diabetes mellitus (T2DM), another
risk factor of AD [8,9,10,11], is a metabolic disorder characterised
by insulin resistance, relative insulin deficiency and glucose
intolerance [12]. Intriguingly, there is also some evidence of a
synergistic interaction between the APOEe4 allele and T2DM.
Like AD, T2DM is associated with impaired insulin signalling and
cognitive functions [13]. The risk of AD is highest amongst
APOEe4 carriers with T2DM [14] and neuropathological studies
reported the highest number of AD lesions in brain tissue of e4
diabetic patients [14]. However, other studies have produced
conflicting findings and have failed to show an increase in AD-
related pathology in diabetic brain [15,16,17].
Further evidence for a link between insulin signalling and AD
comes from rodent models. However, as in man, these in vivo
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coming from genetic versus dietary, and from type 1 versus type 2
models. Thus, diet-induced insulin resistance accelerates b-
amyloid (Ab) pathology [18], whilst peripheral insulin injection
induces tau phosphorylation [19]. Gene deletion experiments
inducing insulin resistance both reduce Ab deposition [20] and yet
increase tau phosphorylation [21].
Based upon evidence from epidemiology and animal models,
treatments aimed at restoring adequate levels of brain insulin have
been proposed as a therapeutic approach for AD. Reger et al., and
Craft and colleagues found that administration of insulin via
peripheral [22,23] and intranasal [24,25] routes improved
cognition and these effects were more prominent in non-APOEe4
carriers [22,24]. Improved cognitive performance has also been
demonstrated in animals treated with intranasal insulin [26],
which also improved diabetic brain neuropathy [27].
The thiazolidinediones (TZDs), peroxisome proliferator-activat-
ed receptor gamma (PPARc agonists such as rosiglitazone and
pioglitazone, are widely used clinical treatments for T2DM. TZDs
are insulin sensitising drugs that reduce peripheral insulin
resistance and blood glucose levels [28]. In two early clinical
trials, rosiglitazone improved memory and cognition in patients
with mild to moderate AD [29,30] in an APOE-dependent
manner [30]. More recently pioglitazone also preserved cognitive
function in AD [31]. Consistent with these observations, treatment
with the same insulin sensitising agents in experimental models
attenuated learning and memory deficits [32], reduced the
accumulation of Ab, reduced Ab42 levels and reduced levels of
inflammatory markers [33]. PPARc activation has also been
shown to reduce the phosphorylation of tau in vitro [34], whilst the
overexpression of PPARc reduces the accumulation of Ab [35,36].
These and many other reports lend credence to the hypothesis
that brain insulin resistance leads to AD pathological processes
and thereby support the notion that PPARc agonists such as the
TZDs might be useful therapeutic agents. The observations in
man that increased risk of AD with T2DM is APOE dependent,
that insulin affects Ab pathology in an APOE dependent manner
and that in the early clinical trials with TZDs there was a
stratification of effect by APOE led to the hypothesis that induced
insulin resistance and subsequent treatment with TZDs in animal
models would have APOE dependent effects on ‘downstream’ AD
pathology, specifically tau phosphorylation. In order to explore
this we have utilised an APOE ‘humanised’ mouse model lacking
the mouse APOE gene with human APOEe3o re4 knocked in.
We induced insulin resistance in these animals and subsequently
treated either with or without PPARc treatment. In the first study,
our data shows diet-induced insulin resistance reduces tau
phosphorylation at 3 epitopes, independent of APOE genotype.
In the second of these studies, pioglitazone treatment led to a
significant reduction in tau phosphorylation at the Ser202/Thr205
epitope in APOEe3 animals only, the reverse in APOEe4 mice was
observed.
Results
APOE mice develop diet-induced type 2 diabetes
mellitus-like insulin resistance
Insulin resistance was induced by feeding APOE mice a high
(60%) fat diet (HFD), or low (10%) fat diet (LFD) for 32 weeks.
Throughout this period all APOE mice fed on a HFD gained more
body weight in comparison to the LFD fed animals. Within the
HFD group, APOE KO mice gained the most weight at the end of
the 32 weeks (Figure 1). Oral glucose tolerance tests were taken at
baseline and then at every 6 weeks following initiation of study.
Prior to HFD feeding fasting plasma glucose levels were similar
across genotypes (Figure 2A, B). At week 6 all HFD fed mice had
developed impaired glucose tolerance. In LFD fed mice, plasma
glucose levels reached the maximum at 30 min after glucose
challenge; thereafter glucose elimination occurred by 60 min. In
contrast, there was hardly any glucose elimination between 30 min
and 60 min in HFD fed human APOEe3 and APOEe4 knock-in
mice whilst in the WT and APOE KO mice glucose was
eliminated at a much slower rate compared to LFD fed animals
(Figure 2C, D). Over the duration of high fat feeding, glucose
tolerance became increasingly impaired (Figure 2E-H).
Hyperglycaemia was accompanied by elevations in plasma
insulin. At baseline all groups of mice had similar levels of insulin
(Figure 3). At the end of the 32 weeks study, all the HFD group of
animals had statistically significantly elevated levels of plasma
insulin compared to the LFD group, with the highest in APOEe4
(5.960.5 mg/l), followed by APOEe3 (5.260.6 mg/), APOE KO
(4.860.5 mg/l) and then WT (3.560.6 mg/l) (Figure 3B). Within
each APOE genotype and between the LFD and HFD fed
animals, insulin levels reached a significant difference by 6 weeks
of diet. In contrast, insulin levels in the LFD fed animals increased
by only a small amount (Figure 3A).
Tau phosphorylation is reduced, but APP metabolism is
unchanged, in HFD fed APOE mice
Comparing HFD to LFD animals we found a decrease in tau
phosphorylation in the insulin resistant animals at all epitopes
examined. This decrease was preserved across all genotypes with a
significant decrease in tau phosphorylation in HFD fed WT
animals at the Ser202/Thr205 (p=0.010) and Thr231 epitopes
(p=0.042) and a trend towards reduction at Ser396 (Figure 4A
and 4B). Analysis of all genotypes and all epitopes by ANOVA
shows a significant interaction between diet and tau phosphory-
lation (p,0.001) but no effect of genotype. Combining genotypes
shows a highly significant effect of tau phosphorylation at all three
epitopes (Ser396 p=0.03, Ser202/Thr205 (AT8) p=0.0002 and
Thr231 (AT180) p=0.008) (Figure 4C). With respect to levels of
soluble Ab, we observed no significant changes in Ab40 or Ab42
according to diet within each APOE genotype nor did we observe
changes in APP C-terminal fragments (APP-CTFs) (data not
shown). Given the changes in tau phosphorylation we measured
the level of active tau kinases and tau phosphatases; GSK-3ab by
using an activity dependent phospho-kinase antibody, Cdk5 by
using p35/25 specific antibody and the tau-phosphatase, PP2A.
We also measured the activity of Akt, a member of the insulin
signalling pathway. No significant changes in the brain were found
in GSK-3ab, Cdk5, PP2A or Akt by APOE genotype or diet (data
not shown).
Pioglitazone treatment has genotypic specific effects on
tau phosphorylation at the Ser202/Thr205 epitope
Previously, pioglitazone has been shown to alter insulin
sensitivity in mice and has been suggested as a possible approach
to disease modification in AD. Therefore we treated APOE mice
with pioglitazone during the final three weeks of HFD feeding.
Adiponectin was measured to show pioglitazone treatment was
effective over time. Plasma adiponectin levels increased signifi-
cantly after 3 weeks of drug treatment (data not shown) [37]. In
WT animals there was no consistent and no significant effect on
tau phosphorylation. However, there was a genotypic effect at the
Ser202/Thr205 epitope with pioglitazone treated APOEe3 mice
showing a decrease in tau phosphorylation (p=0.012) and the
reverse, a significant increase in tau phosphorylation in APOEe4
APOE Dependent Effects of Diet and Pioglitazone
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When combining genotypes we found no changes in tau
phosphorylation based on pioglitazone or vehicle treatment groups
in any of the three phospho-tau epitopes (Ser396, Ser202/Thr205
or Thr231) (Figure 5).
Given the change in tau phosphorylation at the Ser202/Thr205
epitope, again we measured the level of active tau kinases GSK-3ab
and Cdk5, the tau-phosphatase, PP2A and changes in Akt, a
component of the insulin signalling pathway. However, we found no
significant changes correlating to the genotypic effect (data not shown).
Pioglitazone treatment on APP processing or soluble Ab
levels in APOE animals
Pioglitazone treatment has been shown to lower amyloid load in
animal models [33,38]. In our study, APOE KO animals fed a
HFD showed a trend for higher levels of soluble Ab40 and Ab42
compared to all other APOE genotypes (Figure 6). No effects of
pioglitazone were observed in relation to Ab42 at any genotype.
No effects of pioglitazone on Ab40 were observed in either WT or
APOEe3 or APOEe4 animals but there was a significant reduction
in APOE KO animals. We note however that APOE KO animals
Figure 1. Body weight increases in HFD fed mice. Body weight of APOE KO, APOEe3, APOEe4 and WT mice over 32 weeks of A) LFD and B) HFD,
starting from 3 months of age. Values are mean6SEM, n=10-12. Body weights in A) and B) reached ***p,0.001 by t-test at all weeks indicated
compared to WT mice. Significance is indicated by * APOE KO,
+ APOEe3, ‘ APOEe4.
doi:10.1371/journal.pone.0016991.g001
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then at 6 weekly intervals. Animals were fasted overnight. The next morning, animals were placed in a warming chamber prior to blood sampling and
blood was taken by direct venopuncture. Mice were then given a single oral dose of glucose (3 g/kg p.o dose volume 10 ml/kg) and serial blood
samples collected from the tail tip post-dose at 30, 60, 90, 120 and 180 mins. Glucose levels were accessed using a blood glucose meter. Graphs show
plasma glucose concentrations at the beginning, at week 6, week 24 and week 32 of APOE KO, APOEe3, APOEe4 and WT mice fed A, C, E, G) LFD and
B, D, F, H) HFD. Values are mean6SEM, n=10–12. *p,0.05, **p,0.01; ***p,0.001 versus WT mice by t-test. Significance is indicated by * APOE KO,
+ APOEe3, ‘ APOEe4.
doi:10.1371/journal.pone.0016991.g002
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represent regression to the mean in a single genotype.
Changes in APP processing of holo APP to APP-CTFs (C83,
C89 and C99) did not differ between treatment groups or within
each APOE genotype (data not shown).
Discussion
There is increasing awareness of modern lifestyles and their
effect on disease progression; including the increasing prevalence
of lifestyle induced T2DM. The risk of AD is increased in diabetics
[9]. Although the mechanisms underlying this are not yet clear,
evidence from animal models has provided some clues towards the
underlying cause.
Previous in vivo studies investigating the effect of diabetes on AD
pathology have produced ambiguous findings. The streptozotozin
(STZ) approach, commonly used to model T1DM, has been shown to
cause increased tau phosphorylation [39,40,41,42,43] and/or in-
creased Ab production in brain [41,44,45]. In the same way, T2DM
m o d e l s ,f o re x a m p l ed b / d bo rh i g hf a tf e dm i c eh a v es h o w ni n c r e a s e d
levels of Abor increased tau phosphorylation and tau cleavage [43,46].
However, other studies report no such changes [44,47]. Further
T2DM models combining diet with transgenic AD models have not
only shown increased Ab burden [18,48] but also increased levels of
tau [49]. Additionally, gene knockout models for IRS2 and the insulin
receptor have shown increased tau phosphorylation [20,21,50] whilst
other studies observed opposite findings [19].
Figure 3. APOE mice develop diet-induced T2DM- like insulin resistance. Plasma insulin levels were measured in APOE KO, APOEe3, APOEe4
and WT mice over 32 weeks of feeding with A) LFD and B) HFD. Blood samples from the tail vein at each OGTT were collected and plasma was
analysed for insulin by ELISA. Values are mean6SEM, n=10–12. In A) plasma insulin levels in all LFD animals reached *p,0.05 by t-test compared to
WT mice. In B) plasma insulin levels in HFD fed animals reached *p,0.05 or ***p,0.001 by t-test compared to WT mice as indicated. Significance is
indicated by * APOE KO,
+ APOEe3, ‘ APOEe4.
doi:10.1371/journal.pone.0016991.g003
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reduces tau phosphorylation compared to LFD fed animals. This
is contrary to a recent study finding no effect of diet on tau
phosphorylation, despite an increase in tau gene expression [47].
As this was a study of young mice (4 weeks compared to 11 months
in our study) and relatively short term diet (16 weeks compared to
32 weeks in our study) it is likely that effects on tau
phosphorylation we observe are due to chronic HFD in older
mice. Our observation also goes somewhat against the idea that
peripheral hyperinsulinemia promotes tau pathology, as reported
in an earlier study [19]. However, in this study an acute insulin
challenge (20 min peripheral injection) was shown to increase tau
phosphorylation. This is not comparable to the data reported here
where tau phosphorylation is reduced in the context of chronic
HFD induced hyperinsulinemia; arguably a model more reflective
of diet induced hyperinsulinemia in man. In a recent clinical study
by Reger and colleagues, intranasal insulin raised the level of brain
insulin and improved memory in AD patients [25]. Improved
cognitive performance has also been demonstrated in animals
treated with intranasal insulin, which also improved diabetic brain
neuropathy [27]. It is possible that the peripheral hyperinsulin-
emia in the HFD animals in this study may induce increased entry
of insulin into the brain, which, in the absence of brain insulin resistance,
results in a reduction in the levels of phosphorylated tau.
Furthermore in contrast to previous studies, we found tau
phosphorylation was independent of APOE genotype
[51,52,53,54,55]. Whilst we are unable to provide a full
explanation for this, one possible source of discrepancy is the
difference between our study and in both papers by Tesseur [52]
and Harris [54] in the use of transgenic mice expressing APOEe3
and APOEe4 in neurons. Previously, cellular origin of apoE in the
brain has been shown to effect its actions-no effect of genotype on
apoE excitoprotection was observed when expressed in astrocytes
whereas apoE4 but not apoE3 was excitotoxic when expressed in
neurons [56]. It is possible that such differences in the models used
in the experiments might underlie the differing observations.
The TZD, pioglitazone, is a potent synthetic PPARc agonist
that targets PPARs, members of the NRC1 class of the nuclear
hormone receptor superfamily of ligand-activated transcription
factors that are expressed in a variety of cell types. Pioglitazone has
a higher permeability through the blood brain barrier (BBB)
compared to rosiglitazone [57]. Our data shows that pioglitazone
Figure 4. Tau phosphorylation is reduced in HFD fed APOE mice, independent of genotype. The frontal cortex from APOE mice were
homogenised in sucrose homogenisation buffer, lysates were then immunoblotted with the indicated antibodies. A) Western blot of tau antibodies in
frontal cortex of APOE KO, APOEe3, APOEe4 and WT mice fed LFD or HFD. B) Density of phosphorylated tau normalised against total tau. C) Tau
phosphorylation is dependent on diet. Phosphorylated tau is normalised to total tau, data is grouped by diet. *p,0.05; **p,0.01; ***p,0.001 by
t-test.
doi:10.1371/journal.pone.0016991.g004
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phospho-epitope of tau; in HFD fed and pioglitazone treated
APOEe3 animals, a further reduction of tau phosphorylation was
observed in comparison to e3 animals treated with vehicle. The
reverse, an increase in tau phosphorylation was observed in
pioglitazone treated APOEe4 animals. Whilst in the APOE KO or
murine APOE animals, no significant changes in tau phosphor-
ylation by pioglitazone treatment were detected. Our results are
consistent with results from a rosiglitazone clinical trial in which
treatment improved cognition in APOEe4 negative patients with
mild to moderate AD [30] and a recently published paper that
observed APOE isoform dependent effects of rosiglitazone in
adipose tissue [58]. As mentioned earlier, there is some evidence of
a synergistic interaction between the APOEe4 allele and T2DM
and the risk of AD is highest amongst APOEe4 carriers with
T2DM [14]. Evidence on mitochondrial dysfunction as part of the
pathophysiology of both AD [59] and T2DM [60] is also
emerging. Greater mitochondrial dysfunction has been detected
in AD APOEe4 carriers [61] and significant evidence show that
this is the cause of apoE4 protein fragments [62], as apoE4 is more
susceptible to degradation compared to the apoE2 and apoE3
isoforms [63]. One hypothesis is that the formation of C-terminal
truncated fragments by neuron-specific cleavage of the apoE4
protein escapes through the secretory pathway, enters the cytosol
and interacts with mitochondria via its hydrophobic lipid-binding
region [64]. This leads to perturbation of mitochondrial function
and hence diminishes mitochondrial participation in glycolytic
processes. Via the same route apoE4 truncated fragments can also
induce tau phosphorylation, as shown in vivo and in vitro
[63,64,65,66,67,68]. Since a direct role of PPARc agonism is to
stimulate mitochondrial biogenesis [69,70,71,72], this suggests that
perhaps neurotoxic C-terminal fragments in our APOEe4 mice
caused excessive damage to mitochondria in neurons. According-
ly, APOEe4 mice did not respond to pioglitazone like APOEe3
mice. A higher dose of pioglitazone may possibly overcome the
detrimental effects of apoE4 we observed.
According to the amyloid cascade hypothesis of AD, it is the
formation or deposition of Ab that initiates the formation of
neurofibrillary tangles [73]. We examined the levels of soluble
Ab40 and Ab42 by ELISA and also the processing of APP by
western blotting in our insulin resistant animals with and without
pioglitazone treatment. Surprisingly, we found no changes in
APOE knock in animals. Our findings oppose the findings by two
studies; Ho et al., who found diet-induced insulin resistance
promoted generation of Ab40 and Ab42 in the brain of Tg2576
mice [18] and from a very recent study which found apoE isoform
dependent effects on Ab levels in PDAPP mice [74]. In both of
these studies by Ho et al., and Bales et al., the use of APP transgenic
animals predisposes the animals to amyloid pathology. This may
allow both authors to detect an effect with diet or APOE genotype,
which we failed to find. In our HFD fed APOE KO animals we
detected a trend of higher levels of soluble Ab40 and Ab42 in
comparison to animals with the APOE gene. The idea that APOE
KOs cannot clear Ab from brain has been suggested [75] and
implies that the clearance of Ab from the brain to the periphery
requires apoE [74] and is mediated by transport of apoE-Ab
complexes across the BBB via LRP-1 [75]. Further, our results did
not replicate the finding of reduction in Ab levels following
pioglitazone treatment, as reported in two earlier in vivo studies
using Tg2576 mice [38] and APPV717l mice [33]. This is most
likely due to different mouse models and/or diet may play a part
in the formation of Ab species. Numerous studies have reported
the role of apoE in the periphery [76], in our study we report for
the first time the combined effect of apoE and insulin in the brain
in vivo. Our data therefore suggests that in our APOE model of
diet-induced T2DM, tau phosphorylation arises due to some
process downstream of Ab.
In both studies; HFD versus LFD and HFD with pioglitazone
treatment, we did not detect any changes in activation of members
of the insulin signalling pathway (Akt, GSK-3ab), tau kinases
(GSK-3ab, Cdk5) or tau phosphatase (PP2A). The lack of
differences in Akt, GSK-3av or Cdk5 phosphorylation indicates
Figure 5. Pioglitazone treatment selectively lowers tau phosphorylation at the Ser202/Thr205 epitope. APOE mice fed HFD for 32
weeks were treated with pioglitazone or vehicle for the final 3 weeks. A) ptau Ser396, B) Ser202/Thr205 (AT8), C) Thr231 (AT180). *p,0.05 by t-test.
doi:10.1371/journal.pone.0016991.g005
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phosphorylation. However, this was not due to PP2A as we
detected no changes in this tau phosphatase. Despite our findings,
many tau phosphatases and kinases have been identified to date
[77] and further examination of these may help us identify the
possible candidates responsible for dephosphorylation of HFD-
induced tau phosphorylation, such as PKA, JNK, MAP Kinases
and PTEN. Furthermore, it is probable that the period required to
increase sufficient levels of insulin in the brains of these animals by
HFD feeding lead to a failure in detecting changes in the insulin
signalling cascade which may have occurred transiently at an
earlier time point.
In conclusion, diet-induced insulin resistance appears to induce
changes in tau phosphorylation due to peripheral hyperinsulin-
emia independent of APOE genotype. The lowering of tau
phosphorylation by pioglitazone treatment in insulin resistant
animals indicates that human APOEe3 is the isoform most
responsive to treatment. However, prospective studies are required
Figure 6. Levels of soluble Ab40 and Ab42 in HFD fed mice treated with or without pioglitazone. Ab A) x-40 and B) x-42 was analysed by
ELISA in the frontal cortex of APOE mice fed HFD and with or without pioglitazone treatment. *p,0.05 by t-test.
doi:10.1371/journal.pone.0016991.g006
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importance between brain and peripheral insulin resistance.
Methods
Ethics Statement
All animal procedures were reviewed and approved by the
GlaxoSmithKline Animal Care and Use Committee, and were
performed in accredited facilities in accordance with institutional
guidelines and the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, National
Research Council). For the study, the Project License number was
80/01892 and the 3 SHOP numbers (protocols) were SP08-01474,
SP08-03665 and SP09-00223. Both Project license number and
SHOP went through the ethical review process.
Animals and tissue preparation
Mice with human APOE genes replacing murine APOE genes
(henceforth described as ‘APOE mice’) were generated as
published [78,79,80]. In brief, the mice were created by gene
targeting of the endogenous murine APOE gene locus with the
human APOE alleles; APOEe3 or APOEe4. Consequently mice
expressed human apoE isoforms under the control of murine
APOE regulatory sequences and have very similar apoE
expression levels to the non-transgenic apoE expressing mice.
Diet study. 3 months old male APOE knockout, APOEe3-
transgenic and APOEe4-transgenic mice, together with back-
ground strain C57BL6 mice were kept on a high fat (60% fat)
(n=12 per genotype) or low fat (10% fat) diet (n=12 per
genotype) (Research Diets, D12492 and D12450B respectively) for
32 weeks. Animals were housed individually under controlled
conditions of temperature and lighting and given free access to
food and water. Metabolic changes were assessed until insulin
resistance developed in mice fed on the high fat diet (HFD).
Treatment study. All animals at 3 months of age were given a
HFD (Research Diets, D12492) for 32 weeks. During the last 3 weeks
of diet, treatment group animals (n=12 per genotype) were orally
dosed with pioglitazone (20 mg/kg p.o.) whilst the vehicle group
(n=12 per genotype) received 1% methylcellulose. Animals were
dosed twice daily (8 am and 8 pm). On day 1 blood was removed by
direct venopuncture from the tail vein before dosing began for
baselinereadings.Anadditional bloodsamplewascollected following
3 weeks treatment and used to assess metabolic changes.
Assessment of metabolic changes. Glucose tolerance tests
were conducted to assess the level of circulating glucose prior to
commencing each study and then at 6 or 12 weekly intervals
following the initiationof study. Animals were fasted overnight. The
next morning, animals were placed in a warming chamber prior to
blood sampling and blood was taken by direct venopuncture. Mice
were then given a single oral dose of glucose (3 g/kg p.o dose
volume 10 ml/kg) and serial blood samples collected from the tail
tip post-dose at 30, 60, 90, 120 and 180 min. Glucose levels were
accessed using a blood glucose meter (Ascensia, UK). Blood samples
collected from the tail vein were centrifuged at 30006g for 5 min,
plasma was aliquoted into separate tubes then stored at -80uC until
analysis with commercial ELISA kit for insulin (DRG, Germany).
Tissue preparation. At termination of each study brains
were removed, the frontal cortex was subdissected and stored at -
80uC until use.
Protein extraction
The frontal cortex region was weighed whilst frozen and then
homogenised rapidly in 10 fold volume of a detergent free tissue
homogenisation buffer (250 mM sucrose, 20 mM Tris-HCl (pH
7.4), 1 mM EGTA, 1 mM EGTA, 100 mM PMSF, 1 mini
complete protease inhibitor cocktail tablet (Roche, UK) and 1
mini complete phosphatase inhibitor cocktail tablet (Roche, UK))
on ice. A sample of total brain homogenate was collected and
stored at 280uC until use in Ab ELISA. Homogenates were then
centrifuged at 47,000 rpm for 20 min at 4uC in a Beckman TLA
55 rotor (Beckman, Palo Alto, CA, USA). The soluble supernatant
(S1 fraction) was collected and the pellet resuspended in a same
volume of the above buffer with the addition of 1% Triton-X 100,
then subjected to centrifugation again. The resultant supernatant
(S2 fraction) was collected and stored at 280uC with the S1
fraction and the pellet, P2 until use.
Western blotting
8% Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). S1 and S2 samples were
diluted in an equal volume of 26 reducing laemmli sample
buffer (BioRad, UK) and boiled at 100uC for 5 min. Samples were
separated on 8% SDS-PAGE gels at 150 V for 1 h at room
temperature (RT). Proteins were then transferred onto
nitrocellulose membranes at 80 V for 1 h at RT. Blots were
incubated in a blocking solution containing 5% skimmed milk
(Marvel) in phosphate buffered saline with 0.1% tween (PBST) for
1 h at RT then probed with primary antibody overnight at 4uC.
The blots were washed three times with PBST then incubated with
either goat anti-rabbit or goat anti-mouse secondary antibodies
conjugated to fluorophors (Molecular Probes, Invitrogen) emitting
at wavelengths of either 700 or 800 nm for 1 h at RT. Blots were
washed three times again with PBST. Proteins were detected using
an Odyssey infrared imager (Licor, UK) and densitometry
performed using ImageJ.
16% Tricine gradient gels. S2 samples were diluted in an
equal volume of 26 Tris-glycine SDS sample buffer containing
NuPage sample reducing agent (Invitrogen, UK) and heated for
3 min at 85uC. Samples were spun briefly then separated on 16%
Tricine gradient gels (Invitrogen, UK) at 130 V for 2 h at RT.
Proteins were then transferred onto 0.2 mm pore size nitrocellulose
membranes (Invitrogen, UK) at 200 mA for 2 h at RT. Blots were
boiled by microwave for 5 min in PBS then incubated in a
blocking solution for 1 h at RT then probed with primary
antibody overnight at 4uC. The blots were washed three times
with PBST then incubated with either goat anti-rabbit or goat
Table 1. List of primary antibodies.
Antibody Type Source
AT8 (Ser 202/Thr205) Mouse monoclonal Pierce
AT180 (Thr231) Mouse monoclonal Pierce
Phospho Tau (Ser396) Mouse monoclonal Cell Signaling Technology
Total Tau Rabbit polyclonal Cell Signaling Technology
Phospho-GSK-3ab (Ser21/9) Rabbit polyclonal Cell Signaling Technology
Total GSK-3ab Mouse monoclonal Stressgen
Phospho-Akt (Ser473) Rabbit polyclonal Cell Signaling Technology
Total Akt Rabbit polyclonal Cell Signaling Technology
Phospho-PP2A (Tyr307) Rabbit polyclonal Cell Signaling Technology
Total PP2A Goat polyclonal Santa Cruz
p35/25 Rabbit monoclonal Cell Signaling Technology
Anti-APP 369 Rabbit polyclonal J Buxbaum
doi:10.1371/journal.pone.0016991.t001
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antibodies (GE Healthcare, UK) for 1 h at RT. Blots were washed
three times again with PBST. Immunoreactivity was visualised
using enhanced chemiluminescence reagents (GE Healthcare,
UK), x-ray film (Fuji, UK) and developer. ImageJ was used for
quantification.
Antibodies
All antibodies (table 1) were used at 1:1000 dilution in blocking
solution PBST containing 5% milk. Protein bands were normal-
ised to b-actin antibody purchased from Abcam, used at 1:5000
dilution. Fluorophore tagged secondary antibodies (Molecular
Probes, Invitrogen) were all used at 1:6000. All HRP-conjugated
secondary antibodies (GE Healthcare, UK) were used at 1:5000.
Abeta ELISA
Levels of mouse soluble Ab 1-40 and Ab 1-42 were measured
using the chemiluminescent BetaMark Beta Amyloid x-40 and x-
42 ELISA kits (Covance) according to the manufacturer’s
instructions. Briefly, total brain homogenates from the frontal
cortex were diluted in working incubation buffer containing HRP
detection antibody then loaded in duplicate onto the antibody
coated plate. The ELISA plate was incubated overnight at 4uC.
The plate was washed 5 times before addition of chemilumines-
cent substrates and read using a Wallac luminometer (Perkin
Elmer).
Statistics
Statistical significance was performed using the student’s t-test
and p,0.05 was considered significant. Data are presented as
mean6SEM.
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